$3,000.00
PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Explore and visualize revenue dynamics in Celgene’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.
6 OVERVIEW
6 Snapshot
6 Model updates
7 Analysis structure
9 Q2 2018 REVIEW
9 Celgene delivers an important turnaround quarter
9 Celgene’s outlook strengthened by key pipeline wins
10 Bibliography
11 Q1 2018 REVIEW
11 Celgene reports Q1 2018 product sales of $3.5bn, up by 19.6% compared to Q1 2017
12 Prothena deal supports growing neuroscience focus
12 Key 2018 catalysts
13 Bibliography
14 Q4 2017 REVIEW
14 Celgene finishes 2017 strongly with Juno and Impact acquisitions
15 Q4 2017 events
15 Tax reform has provided the impetus for acquisitions
16 Clinical updates
17 Bibliography
18 Q3 2017 REVIEW
18 Celgene’s outlook is tempered as Otezla loses momentum
18 Otezla revenue disappoints as key oncology products continue to grow
20 Clinical holds will not hinder Revlimid and Pomalyst growth
20 Price hikes for Revlimid and Pomalyst will help plug Otezla hole
20 Phase III failure of GED-0301 emphasizes the importance of ozanimod to Celgene’s long-term growth
21 Q3 2017 events
21 Q4 2017 will be a key period for Celgene
22 Bibliography
23 STRATEGY ANALYSIS
23 Celgene is a global leader in oncology
23 Revlimid will experience strong mid-term growth
23 Strong investor pressure
23 Celgene looks to cellular immunotherapy to drive future growth
24 Long-term outlook
24 Celgene’s SWOT analysis
26 Celgene’s key events and catalysts
27 Bibliography
28 PORTFOLIO ANALYSIS
30 Q2 2018
32 Bibliography
34 FACTS AND FIGURES
34 Celgene’s prescription pharma sales outlook
34 Celgene’s regional pharma sales outlook
36 Celgene’s therapy area dynamics
43 Celgene’s top 10 products over 2017–27
43 Celgene’s growth drivers and resistors
46 Celgene’s lifecycle analysis
48 Celgene’s pipeline analysis
50 Celgene’s M&A strategy and history
LIST OF FIGURES
16 Figure 1: JCAR017 Phase I data in relapsed/refractory DLBCL presented at ASH 2017, and Yescarta and Kymriah Phase II data shown at ASCO 2017 and ASH 2017
34 Figure 2: Celgene’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
36 Figure 3: Celgene’s therapy area dynamics, 2017–27
43 Figure 4: Celgene’s top 10 product sales ($m), 2017–27
46 Figure 5: Celgene’s launch/core/expiry/generic portfolio configuration, 2017–27
48 Figure 6: Celgene’s pipeline overview
LIST OF TABLES
29 Table 1: Celgene’s sales by therapy area ($m), 2017–27
35 Table 2: Celgene’s prescription pharmaceutical sales by region ($m), 2017–27
37 Table 3: Celgene’s sales by therapy area ($m), 2017–27
39 Table 4: Celgene’s oncology portfolio sales, by product ($m), 2017–27
42 Table 5: Celgene’s I&I portfolio sales, by product ($m), 2017–27
44 Table 6: Celgene’s key products, 2017–27
47 Table 7: Celgene’s sales by launch, core, expiry, and generic portfolio ($m), 2017–27
49 Table 8: Celgene’s launch portfolio sales, by product ($m), 2017–27
51 Table 9: Celgene’s key merger and acquisition deals, 2008–18
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!